Manuscripts and Publications

Filters: Keyword is Prospective Studies and Author is Bowler, Russell P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
B
Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, R Barr G et al..  2017.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.. Am J Respir Crit Care Med. 195(4):473-481.
C
W LeMaster B, P Quibrera M, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG et al..  2023.  Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.. Chest. 163(3):515-528.
F
Han MK, Quibrera PM, Carretta EE, R Barr G, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL et al..  2017.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(8):619-626.
R
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
V
Bradford E, Jacobson S, Varasteh J, Comellas AP, Woodruff P, O'Neal W, DeMeo DL, Li X, Kim V, Cho M et al..  2017.  The value of blood cytokines and chemokines in assessing COPD.. Respir Res. 18(1):180.